Article

Systematic Living Evidence for Clinical Trials (SyLECT): a data-driven framework for drug selection in clinical trials in motor neuron disease

2025-03-10

Abstract excerpt

Despite many promising preclinical studies and decades of clinical trials, there remains a paucity of effective disease-modifying drugs in motor neuron disease. We aimed to develop a systematic and structured data-driven framework to identify, evaluate and prioritise candidate drugs for clinical trials, specifically for the Motor Neuron Disease-Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART; NCT04030287...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 13510057-d967-5f92-b36f-155feb7dd26f
DOI: 10.1101/2025.03.09.25323612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Systematic Living Evidence for Clinical Trials (SyLECT): a data-driven framework for drug selection in clinical trials in motor neuron diseaseDOI 10.1101/2025.03.09.25323612Read

A Systematic Approach to Identify Neuroprotective Interventions for Motor Neuron DiseaseSemantic proximity Read

Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trialsSemantic proximity Read

Statistical Analysis Plan for the Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART)Semantic proximity Read

Optimal Clinical Trials Platform for Progressive Multiple Sclerosis (OCTOPUS): protocol for an international, multi-arm, multi-stage, platform, randomized controlled, double-blind, phase 3 clinical trialSemantic proximity Read

Methods for Neuroscience Drug Development: Guidance on Standardization of the Process for Defining Clinical Outcome Strategies in Clinical TrialsSemantic proximity Read

From Bench to Bedside: A Meta-Analysis of Translational Research in Duchenne Muscular DystrophySemantic proximity Read

Drug Repurposing for Parkinson’s Disease: A Large-Scale Multi-Cohort StudySemantic proximity Read

A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasiaSemantic proximity Read

A 5-repurposed drug candidates identified in motor neurons and muscle tissues with amyotrophic lateral sclerosis by network biology and machine learning based on gene expressionSemantic proximity Read

D <sup>R</sup> e <sup>A</sup> mocracy: A Method to Capitalize on Prior Drug Discovery Efforts to Highlight Candidate Drugs for RepurposingSemantic proximity Read

Evaluation of Clinical Outcomes of Riluzole monotherapy and Riluzole based adjunctive interventions in Amyotrophic Lateral Sclerosis: A meta-analytic and unsupervised clustering approachSemantic proximity Read

Development of a Core Outcome Set for Neurological Disorders (COS-Neuro): an AI-Assisted Thematic Framework AnalysisSemantic proximity Read